Kalaris Therapeutics filings document formal disclosures for a Nasdaq-listed clinical-stage biopharmaceutical company developing retinal-disease therapeutics. The record includes 8-K reports on operating and financial results, Regulation FD clinical presentations for TH103, material-event disclosures, capital-structure matters, and executive officer changes.
Proxy materials describe annual meeting and shareholder voting matters, while security disclosures identify Kalaris common stock under the KLRS ticker. Clinical disclosures focus on TH103 safety, tolerability, pharmacokinetics, early efficacy information, manufacturing updates, and the company's retinal-disease development plans.
Kalaris Therapeutics reported first‑quarter 2026 results and highlighted progress in its retinal disease program TH103. As of March 31, 2026, the company held $104.9 million in cash, cash equivalents and marketable securities and expects this to fund operations into the fourth quarter of 2027 and through key clinical milestones.
Research and development expenses rose to $7.6 million from $6.0 million a year earlier as additional clinical sites were opened and patients enrolled. General and administrative expenses were stable at $4.3 million. Net loss was $10.9 million, compared with $10.2 million in the prior‑year quarter, with no revenue reported.
The company has begun patient screening in its Phase 1b/2 trial of TH103 for neovascular age‑related macular degeneration and has manufactured new clinical material for upcoming dosing. It anticipates preliminary Phase 1b/2 data in the first half of 2027 and continues to plan Phase 3 trials targeted for initiation by year‑end 2027.
Kalaris Therapeutics, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 3, 2026 at 11:30 a.m. Eastern. Proposals include electing three Class III directors, an advisory say-on-pay vote, an advisory vote on say-on-pay frequency, and ratifying Deloitte & Touche LLP as auditor.
The record date is April 6, 2026, with about 11,496,146 common shares outstanding for quorum. Kalaris is classified as a “smaller reporting company” and a “controlled company,” allowing scaled disclosures and some exemptions from Nasdaq independence requirements. The meeting will be held exclusively online via www.proxydocs.com/KLRS.
Kalaris Therapeutics, Inc. registered up to $100,000,000 of common stock for sale through an at-the-market program with TD Securities (USA) LLC (TD Cowen). The prospectus permits sales from time to time at market prices, including negotiated block trades or sales on The Nasdaq Global Market.
The prospectus states 22,902,418 shares were outstanding as of December 31, 2025 and discloses an illustrative assumed offering price of $5.79 per share used to show dilution. Compensation to TD Cowen is up to 3.0% of gross proceeds and the company may sell shares to TD Cowen as principal. Net proceeds are intended for general corporate purposes including R&D, clinical development, working capital and potential acquisitions.
Kalaris Therapeutics, Inc. is registering for resale up to 5,000,000 shares of its common stock, consisting of 4,200,000 outstanding shares held by selling stockholders and 800,000 shares issuable upon exercise of pre-funded warrants. The company will not receive proceeds from resales, but will receive cash if pre-funded warrants are exercised at an exercise price of $0.0001 per share. The registration implements registration rights granted in connection with a December 17, 2025 private placement in which the company raised aggregate gross proceeds of approximately $50.0 million through the sale of common stock and pre-funded warrants. Resales may occur from time to time in various manners described under the plan of distribution; certain exercise and beneficial ownership limits (a 4.99% default cap, up to 19.99% if elected) apply to the pre-funded warrants.
Kalaris Therapeutics, Inc. announced that Chief Financial Officer Matthew Gall will resign effective April 14, 2026. In connection with his departure, Brett Hagen, the current Chief Accounting Officer and principal accounting officer, will also serve as the company’s principal financial officer from the same date.
The filing outlines Mr. Hagen’s prior senior finance roles at several biopharmaceutical companies and his academic background in accounting and finance. It also notes that he has no family relationships with directors or officers, no related-party transactions requiring disclosure, and that his compensation arrangements remain unchanged.
Kalaris Therapeutics, Inc. is registering up to $350,000,000 of securities on a shelf, including an $100,000,000 program to sell common stock under a sales agreement.
The prospectus covers debt securities, common stock, preferred stock, subscription rights, warrants and units that may be offered "from time to time"; specific terms and distribution methods will be set forth in prospectus supplements. The company has an at-the-market sales agreement with TD Cowen that permits sales of up to $100,000,000 of common stock, with compensation up to 3.0%.
Kalaris Therapeutics, Inc. registers for resale up to 5,000,000 shares of its common stock, consisting of 4,200,000 outstanding shares and 800,000 shares issuable upon exercise of pre-funded warrants. The prospectus covers resales by the selling stockholders; the company will not receive proceeds from resales, although it would receive cash if pre-funded warrants are exercised at an exercise price of $0.0001 per share. The shares were issued in a private placement that generated approximately $50.0 million in gross proceeds at a price of $10.00 per share (and pre-funded warrants at $9.9999), and the registration statement was filed to satisfy registration rights. Shares outstanding were 22,928,303 as of February 28, 2026. The prospectus permits sales on Nasdaq or other methods described under "Plan of Distribution," and notes a Beneficial Ownership Limitation (default 4.99%, adjustable up to 19.99% with notice).